UNH — UnitedHealth Group Incorporated

As of 2026-10-14 sentiment had visibly turned: the stock closed at $392.53 the day after the 2026-10-13 Q3 report, up 3.9% on the session, +3.92% over one week and +24.42% over six months. The beat was cost-led rather than revenue-led (medical care ratio 88.4% vs 89.9% YoY), FY2026 adjusted EPS guidance was lifted for the third time to at least $20.50, and sell-side reaction was constructive (Bernstein reiterated Outperform, $512 target; Baird moved to $427). Consensus is a Moderate Buy — 43 buy / 7 hold / 2 sell — with an average target near $470-480, roughly 20% above the 2026-10-14 price. The important caveat is that this is a recovery in sentiment, not euphoria: the shares were still -6.64% over three months and 15% below the 52-week high of $461.62, and RSI at 59.13 is constructive but nowhere near overbought.

Revenue is the problem child: from $94.4B in Q4 2023 to $112.7B in Q3 2026, but the growth rate has collapsed — +12.3% YoY in Q4 2025, +2.0% in Q1 2026, +0.4% in Q2 2026, and -0.4% in Q3 2026 ($112,694M vs $113,161M). That's a genuine deceleration, not a blip, and part of it is deliberate (repricing Medicare Advantage and shedding underperforming value-based care contracts), but a flat top line caps how much operating leverage can compound. Margins tell the opposite story: 2025 was the trough (Q3 2025 operating margin 3.81%, Q4 2025 a near-worthless $380M of operating income and $0.011 EPS — clearly distorted by a one-off charge), and 2026 has recovered to 8.05%, 7.13% and 5.82% in Q1/Q2/Q3. On a year-over-year basis every 2026 quarter beat its 2025 counterpart except Q1 (8.05% vs 8.32%), and Q3 2026 GAAP EPS of $4.56 versus $2.59 is a +76% swing. The wrinkle: margins have compressed sequentially through 2026 (8.05% → 7.13% → 5.82%), which may be seasonal (UNH's Q3 is structurally its weakest) or may signal the cost tailwind fading — that distinction matters more than anything else in the next two prints. Cash generation is healthy and cash-backed: TTM free cash flow through Q3 2026 is ~$22.8B (Q3 $4.26B, Q2 $10.25B, Q1 $8.15B, Q4 2025 $0.16B), and the accruals ratio of -0.32% says reported earnings are not running ahead of cash. Balance sheet is stable: equity $104.1B, long-term debt $68.7B, cash $25.8B, though debt is up from $58.3B at year-end 2023 and the current ratio of 0.739 is below 1.

Cheap-to-fair, with the cheapness partly deserved. As of 2026-10-14 UNH traded at $392.525 on a 22.4x trailing P/E (EPS TTM $17.61) versus a 5-year average trailing P/E of 26.33x, and 0.79x sales versus a 5-year average P/S of 1.27x. But the trailing EPS base is artificially depressed by a $0.011 Q4 2025, so the more honest comparison is forward: ~19.1x on FY2026 guidance of at least $20.50, and ~19.4x on the FY2027 consensus of $20.27. That is a 27% discount to the stock's own 5-year average multiple and roughly in line with or modestly above large-cap managed care peers, and it sits alongside a compelling 6.4% free cash flow yield ($22.8B TTM FCF on a $356.5B market cap) and a 2.36% dividend yield — for a 0.615-beta, AA-tier balance sheet franchise consistent with a business that has stabilized. The PEG ratio of -2.506 is meaningless here (it's an artifact of the distorted trailing earnings base) and should be ignored. Verdict: the stock is genuinely cheaper than its own history, but a 19x forward multiple on an expected flat-to-down 2027 consensus is not a deep-value setup — it's fair value for a company whose earnings are recovering but whose revenue has stopped growing.

At ~19x forward, the market is pricing a stabilized MCR and a completed trough, but not a return to the 26x-era multiple or to management's 13-16% long-run EPS growth target. The three 2026 beats have all been cost-driven (medical care ratio, prior-auth/pricing discipline), not demand-driven, so the next leg of upside requires either (a) FY2027 consensus EPS moving meaningfully above the current $20.27 — which would be below FY2026's ≥$20.50 guidance, i.e. an expected down year — or (b) continued multiple expansion as the market gains confidence the MCR improvement is durable. If 2027 revisions drift toward $21.50-22.00 (management has explicitly hinted consensus understates 2027), the stock can plausibly carry a 20x multiple and deliver low-double-digit total return from here; if 2027 really does land at ~$20.27, the shares are roughly efficiently priced at 19x and you're collecting a ~2.4% dividend plus low-single-digit earnings growth, i.e. mid-single-digit annualized. The single most important tell to watch is whether the sequential margin compression within 2026 (8.05% → 7.13% → 5.82%) proves seasonal or structural.

Constructive, not cheap timing. As of 2026-10-14, RSI(14) was 59.13 — above neutral, below overbought — with the stock at $392.525 sitting +4.05% above its 20-day SMA (~$377), +0.87% above its 50-day (~$389) and +9.04% above its 200-day (~$360). It gained 3.92% over the week and 24.42% over six months, but is still -6.64% over three months, meaning this is a recovery from a summer pullback that has just reclaimed the 50-day, not a fresh breakout at a discount. The stock is 53% above its 52-week low of $255.97 and 15% below its 52-week high of $461.62. Entry-timing implication: buying at +4% above the 20-day on the day after an earnings gap is chasing; the earnings-day prior close of $377.76 and the 50-day near $389 are the first support references, and a pullback toward the 200-day around $360 would offer materially better risk/reward than initiating here.

• Medical cost trend / utilization — the dominant swing factor. The Q3 2026 medical care ratio of 88.4% (vs 89.9% YoY) is the entire bull case; any re-acceleration in utilization snaps the recovery narrative and the guidance raises with it.
• Medicare Advantage rate notices and risk-adjustment policy — CMS reimbursement updates and audit intensity are a direct, largely exogenous lever on UNH's largest government book, and the 2027 plan-year rate structure is still being finalized.
• Federal healthcare policy and political risk — ACA subsidy debates, prior-authorization and utilization-management scrutiny, PBM/drug-pricing reform affecting Optum Rx, and ongoing antitrust interest in vertical integration between a payer and a care-delivery/services arm.
• Interest rates — UNH is low-beta (0.615) with $68.7B of long-term debt, so rates matter modestly for refinancing cost and discount rates, but the sector's performance is overwhelmingly dictated by MLR trends and government rate updates rather than the rate cycle.
• Sector rotation into defensives — healthcare's defensive profile is a tailwind for the multiple when growth/tech leadership wobbles, and would amplify any continued MCR improvement.
• Care-delivery and labor cost inflation inside Optum Health — physician group economics and value-based care contract repricing are a slower-moving but real drag on consolidated margins.

• Q4 2026 earnings (estimated 2027-01-26) — the first test of whether FY2026 guidance of at least $20.50 holds and, more importantly, the first substantive look at initial FY2027 framing.
• Finalization of 2027 Medicare Advantage rate structures and enrollment dynamics heading into the next plan year, plus any 2027 CMS rate notice — a direct lever on next year's margin.
• Full implementation of the promised prior-authorization reforms (management targeting a 30% reduction by end of 2026) — reduces regulatory and reputational pressure and could support the multiple.
• Completion of shedding underperforming value-based care contracts — margin accretive if executed cleanly, though it further suppresses reported revenue growth.
• Sell-side EPS revisions toward or above management's implied 2027 trajectory — management has publicly said current 2027 consensus may understate earnings potential; upward revisions would be the cleanest re-rating trigger.
• Continued MCR below 89% — if Q4 2026 shows the sequential margin decline was seasonal, the market can start pricing a normalized earnings base rather than a trough base.

• Medical cost re-acceleration. The entire 2026 beat-and-raise streak is cost-driven; if utilization spikes the way it did in 2025, the MCR snaps back above 89-90% and a raised-guidance cycle reverses very quickly.
• Revenue stagnation. Q3 2026 revenue was down 0.4% YoY, and FY2027 consensus EPS of $20.27 is below FY2026 guidance of at least $20.50 — the market is effectively forecasting a flat-to-down earnings year for a stock that has already rallied 24.4% in six months.
• Regulatory and political overhang. Medicare Advantage rate pressure, risk-adjustment audits, prior-authorization rules, PBM/drug-pricing reform, and antitrust scrutiny of the Optum vertical all represent policy risk outside management's control.
• Sequential margin compression inside 2026 (operating margin 8.05% → 7.13% → 5.82%). If that is structural rather than seasonal, the recovery thesis is materially weaker than the YoY comps suggest.
• Balance sheet and legal overhang. The current ratio of 0.739 is below 1, long-term debt has grown to $68.7B from $58.3B at year-end 2023, and litigation/remediation tied to the 2024 Change Healthcare cyberattack remains an unresolved tail risk.

UNH is a genuinely improving story that is no longer a cheap one. The trough was 2025 (Q4 2025 operating income of just $380M and $0.011 EPS), and Q3 2026 delivered a real inflection — MCR down 150bp YoY to 88.4%, adjusted EPS $4.69 vs ~$4.14 expected, third guidance raise of the year, and a 6.4% TTM free cash flow yield on a business that throws off $22.8B in cash and carries a 0.615 beta. But two things keep me from calling it a buy at $392.53: revenue actually shrank 0.4% YoY in the most recent quarter, and FY2027 consensus EPS of $20.27 sits below FY2026's promised $20.50, so the near-term earnings picture is roughly flat while the shares have already re-rated 24% off their lows. The discount to the 26.3x 5-year average P/E looks wide but is partly an artifact of trough trailing earnings inflating that average — on a forward basis this is a fair 19x, not a bargain. Better entry on a pullback toward the 200-day (~$360), or on evidence that 2027 EPS revisions are moving above $21.

Forward P/E method: 20.0x applied to my FY2027 EPS estimate of $21.50, which grows FY2026's guided floor of $20.50 by ~5% — deliberately below management's 13-16% long-term target and above the $20.27 consensus, splitting the difference between a flat 2027 and management's claim that consensus understates it. The 20x multiple is a discount to the 26.3x 5-year average (inflated by trough trailing earnings) but a premium to managed care peers, justified by Optum's services mix, a 0.615 beta, negative accruals (-0.32%) and a ~6% trailing FCF yield; at $430 the stock would still yield ~5.5% on TTM free cash flow of $22.8B, so the number is consistent with a cash-flow cross-check, not just the multiple.